Epithelial neoplasm

This trial tests whether combining two drugs—pucotenlimab, which helps the immune system attack cancer, and becotatug vedotin, which delivers a toxin directly to tumor cells—can eliminate advanced penile cancer before surgery. Men with high-risk, locally advanced penile squamous …

This phase 2 trial is testing whether giving two drugs before surgery can help people with advanced oral cavity cancer. The drugs, becotatug vedotin and pucotenlimab, are designed to attack cancer cells and boost the immune system. Participants receive three cycles of the combina…

This trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…

This trial tests whether combining two drugs—disitamab vedotin and toripalimab—with or without pelvic lymph node removal can help people with muscle-invasive bladder cancer keep their bladder. Participants, who have HER2-positive tumors and decline bladder removal surgery, will r…

This trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…

This trial is testing an experimental therapy called IOV-5001, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack cancer. The study involves adults with advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, col…

This trial tests whether a single, outpatient treatment using low-thermal argon plasma can clear grade 2 cervical intraepithelial neoplasia (CIN2), a precancerous condition. Participants receive either the plasma treatment, a sham procedure, or standard active surveillance. The m…

This study tests whether giving the immunotherapy drug dostarlimab for a longer period can completely eliminate tumors in people with a specific genetic type of rectal cancer. Participants have stage II or III rectal cancer that is mismatch repair deficient (dMMR) or microsatelli…

This phase 2 trial is testing whether a combination of two immunotherapy drugs, botensilimab and balstilimab, can completely eliminate early-stage rectal cancer in people whose tumors are microsatellite stable (MSS). Participants receive one infusion of botensilimab followed by b…

This phase 2 trial is testing whether the immunotherapy drug sintilimab can eliminate early-stage (I-II) MSI-H/dMMR endometrial cancer without the need for surgery. About 48 participants will receive sintilimab alone every three weeks. The goal is to see if the drug can produce a…

This phase 2 trial is testing whether a three-pronged approach—tumor ablation, immunotherapy (tislelizumab), and chemotherapy—can improve outcomes for people with stage II-IIIB non-small cell lung cancer that can be surgically removed. The goal is to see if this combination can e…

This trial investigates whether adding the immunotherapy drug cemiplimab to standard chemotherapy before surgery can completely eliminate tumors in people with early-stage non-small cell lung cancer (tumors 2 to 3.9 cm). Participants will receive three cycles of the drug combinat…

This trial is testing whether a personalized cell therapy can help women with ovarian cancer that has returned. Doctors will remove a tumor, extract immune cells called tumor-infiltrating lymphocytes (TILs), and boost them in the lab before infusing them back into the patient. Af…

This phase II trial tests whether a personalized DNA vaccine, tailored to each patient's tumor, can keep high-risk liver cancer from coming back after surgical removal. Participants who have no remaining signs of cancer after surgery will receive the vaccine plus an immune booste…

This phase II trial is testing an investigational drug called BL-M09D1 in people with advanced gynecological cancers (such as ovarian, cervical, or endometrial cancer) and other solid tumors that have progressed despite standard treatment. The drug is given by intravenous infusio…

This study tests a device that keeps donor livers cool and oxygenated before transplant, aiming to reduce early liver problems. About 215 first-time liver transplant patients will receive a liver preserved with this method. The goal is to see if it lowers the risk of early graft …

This trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This trial is testing whether CRB-701, a targeted chemotherapy that delivers a potent drug directly to cancer cells, can shrink tumors and extend life in people with recurrent or metastatic oropharyngeal (throat or tonsil) cancer. Participants will have already tried platinum-bas…

This trial tests a new tool called CURTIS, designed to safely remove bladder tumors in one intact piece after they are cut out during surgery. The goal is to see how often the device can successfully retrieve the tumor without breaking it apart, and what the largest tumor size is…

This study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…

This study tests a radioactive drug called 177Lu-DOTA-EB-TATE in 18 adults with a rare thyroid cancer (Hurthle cell) that has spread and not responded to standard radioactive iodine treatment. The drug is designed to seek out and attach to cancer cells. Participants will receive …

This trial tests whether a drug called carfilzomib, given directly to the liver through an implanted pump, is safe for people whose colon, adrenal, or bile duct cancer has spread to the liver and persists after prior pump therapy. Participants receive weekly infusions of the drug…

This phase II trial tests whether combining bevacizumab, a drug that limits blood vessel growth, with PRGN-2012, a vaccine-based therapy, can help adults with recurrent respiratory papillomatosis (RRP) avoid needing more surgeries. RRP causes wart-like growths in the airway that …

This phase II trial is testing whether combining the experimental immunotherapy drug ivonescimab with chemotherapy (paclitaxel) delivered directly into the abdomen can safely and effectively treat people with high-grade metastatic appendiceal adenocarcinoma that cannot be removed…

This trial is testing whether MRI-guided radiation therapy can treat early-stage kidney cancer with fewer side effects than standard CT-based radiation. The study enrolls adults with kidney cancer who are not candidates for surgery or who decline it. Participants receive a single…

This early-stage trial tests a drug called samuraciclib in 15 people with localized pancreatic cancer that can be surgically removed. Participants will take the drug for about two weeks before their planned surgery. Researchers will check safety and look for changes in tumor cell…

This trial tests whether combining an EGFR-targeted pill (EGFR-TKI) with an antibody-drug conjugate (trastuzumab rezetecan) can shrink tumors in people with advanced non-small cell lung cancer that has both an EGFR mutation and HER2 alterations. Participants receive the combinati…

This study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …

This early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein c…

This phase 2 trial tests a combination of a vaccine (TriAdeno) and an immune-boosting drug (N-803) in 52 men with early-stage, low- or medium-risk prostate cancer who are currently on active surveillance. The vaccine targets three proteins found in prostate cancer cells, while N-…

This phase II trial is testing whether adding an experimental immunotherapy drug called AK112 to a standard chemotherapy regimen (gemcitabine, cisplatin, and albumin-bound paclitaxel) can shrink locally advanced gallbladder tumors enough to allow surgery. Adults with gallbladder …

This trial is testing whether adding ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works better than the usual chemo-immunotherapy combination for people with advanced biliary tract cancer. Ivonescimab is a special antibody that targets two proteins: one that h…

This trial tests whether a home-based prehabilitation program, supported by 5G and artificial intelligence, can help gastric cancer patients prepare for surgery after chemotherapy. The program includes personalized exercise, nutrition, and psychological support, all supervised re…

This phase 2 trial is testing a two-step treatment approach for people with advanced HER2-positive breast cancer. First, participants receive an induction therapy with trastuzumab rezetecan. If the disease does not progress, they then move to a maintenance phase combining trastuz…

This trial is testing a device that delivers heated chemotherapy directly into the bladder for people with non-muscle invasive bladder cancer. The goal is to see if the system is safe and works as intended. Participants will receive the treatment and be monitored for side effects…

This trial is testing whether adding a non-invasive ultrasound treatment called histotripsy to the immunotherapy drug durvalumab can strengthen the body's immune response against advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer. Histotripsy uses focused sound …

This phase 2 trial is testing whether combining two immunotherapy drugs—vilastobart and retifanlimab—can shrink tumors in people with metastatic pancreatic cancer that has a BRCA1, BRCA2, or PALB2 gene mutation. Participants receive both drugs by IV infusion over several months. …

This phase 2 trial is testing an experimental drug called xaluritamig in men with metastatic castrate-resistant prostate cancer who had only a partial or stable response to lutetium-177 therapy. The goal is to see if xaluritamig can shrink tumors or lower PSA levels. About 30 par…

This phase 2 trial is investigating whether adding a ketogenic diet and/or high-dose intravenous vitamin C to standard chemoradiotherapy and immunotherapy can improve outcomes for patients with locally advanced rectal cancer that is mismatch repair proficient (pMMR/MSS). The stud…

This pilot study tests whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer who have a complete response to chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either observation or standard surger…

This trial asks whether it is safe to skip the routine removal of impacted teeth before radiation therapy for nasopharyngeal carcinoma. Half of the participants will have the extraction as usual, while the other half will not. The study will compare the risk of jaw bone damage (o…

This early-phase trial is testing a personalized cancer vaccine called BreakVax, designed from each patient's own tumor, in combination with immunotherapy and chemotherapy for advanced triple-negative breast cancer. The goal is to see if this multi-pronged approach can safely boo…

This study tests a combination of an experimental drug (ficerafusp alfa), an immunotherapy (pembrolizumab), and targeted radiation before surgery for people with advanced head and neck cancer that is HPV-negative. About 45 participants will receive these treatments over several w…

This trial compares two endoscopic techniques for removing flat, non-cancerous colorectal polyps that are 10-20 mm in size. One method uses a cold snare (no heat), while the other uses a hot snare with electrocautery. The goal is to see if the cold approach is just as effective a…

This early-stage trial is testing an investigational drug called BL-ARC002 in people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to find a safe dose and to see if the drug shows any signs of shrinking tumors. Participants receive the …

This trial is testing whether switching to a different drug combination after initial chemotherapy can help people with advanced gastroesophageal cancer live longer without the disease worsening. Participants first receive standard chemotherapy plus an immunotherapy drug (tisleli…

This study tests whether precisely targeted radiation (SBRT) can stop or slow the growth of a few resistant spots in metastatic lung cancer patients who are already on targeted therapy (TKI). About 60 adults with EGFR or ALK mutations will receive radiation to those spots, and do…

This phase 2 trial is testing whether adding relacorilant—a drug that blocks a stress-related hormone—to the chemotherapy nab-paclitaxel can shrink tumors in people with recurrent or metastatic cervical cancer. Participants have already tried platinum-based chemo and immunotherap…

This trial is testing whether a blood test that detects cancer DNA can guide the use of durvalumab, an immunotherapy, after standard chemoradiotherapy in patients with stage III lung cancer that cannot be removed by surgery. The goal is to see if giving durvalumab only to patient…

This study compares two smartphone apps designed to help people stop smoking. One app uses a therapy that focuses on mood and behavior, while the other uses standard quitting advice. About 1,800 adult smokers who want to quit in the next month will use one of the apps for 30 days…

This study tests whether adding an experimental drug called SYS6090 to standard cancer treatments can safely and effectively shrink tumors in people with advanced hepatocellular carcinoma, the most common type of liver cancer. Participants will receive SYS6090 combined with bevac…

This trial tests whether an AI tool called SurgDiff can predict how difficult rectal cancer surgery will be, based on MRI scans and patient data. The goal is to help surgeons choose the best surgical approach for each patient, potentially reducing complications. The study involve…

This phase III trial is testing whether adding everolimus to trastuzumab rezetecan helps people with a specific subtype of triple-negative breast cancer (called luminal androgen receptor) live longer without their disease progressing. The study enrolls adults with advanced or met…

This trial is testing whether an experimental drug called SYS6010 can better control advanced head and neck cancer compared to standard single-drug treatments. It involves about 340 adults aged 18-75 whose cancer has returned or spread and who have already tried platinum-based ch…

This study tests whether a fecal microbiota transplant (FMT) — transferring healthy gut bacteria from a donor — can help restore the immune system's ability to fight advanced non-small cell lung cancer in 15 patients whose disease worsened after prior immunotherapy. Participants …

This study tests a device called Vanquish that uses water vapor (steam) to destroy prostate cancer tissue in men with Grade Group 3 intermediate-risk prostate cancer. Fifty participants will receive the treatment and be followed for two years to see if the cancer is reduced and t…

This phase 3 trial is testing whether an investigational drug called ABBV-1480, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for adults with advanced or metastatic squamous non-small cell lung cancer. Particip…

This trial tests an artificial intelligence system called ADTPS that helps doctors remove early-stage esophageal cancer or precancerous lesions using a scope. The AI analyzes live images during the procedure and overlays a suggested cutting path on the screen. Half of the partici…

This trial tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) to standard chemotherapy before chemoradiation can improve outcomes for people with advanced nasopharyngeal cancer. About 60 adults with non-metastatic, EBV-positive nasopharyngeal carc…

This study is for people with advanced non-small cell lung cancer who also have interstitial lung disease (ILD), a condition that causes lung scarring. Many doctors avoid treating these patients due to risks of worsening ILD. The trial will test a specific chemotherapy as first t…

This phase 2 trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy (FLOT before surgery, TS-1 after) can improve outcomes for people with resectable gastric or gastroesophageal junction cancer. The study aims to see if this combination increas…

This trial is testing whether treating only part of the breast with radiation is as effective as treating the whole breast in women with early-stage, low-risk breast cancer. Participants are women aged 40 and older who had breast-conserving surgery and did not have a sentinel lym…

This trial is testing whether artificial intelligence can create 'digital twin' models of esophageal cancer patients to predict how they will respond to a combination of immunotherapy and chemotherapy. The study will compare the AI's predictions against real outcomes in patients …

This trial is testing whether a special PET scan can help predict how well the drug elacestrant works in people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has not responded to prior hormone therapy. All participants will take elacestrant daily…

This trial tests whether giving two immunotherapy drugs—pembrolizumab and cetuximab—before surgery can shrink advanced oral cancers linked to betel-nut chewing. The study enrolls 20 people in the Northern Mariana Islands who have not yet received treatment. Researchers will measu…

This trial is testing whether an experimental oral drug, HS-10504, can slow the progression of advanced non-small cell lung cancer in people whose tumors carry a specific EGFR C797S mutation and have already failed prior EGFR inhibitor therapy. Participants will be randomly assig…

This phase 2 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to the standard immunotherapy pembrolizumab can better control recurrent or metastatic head and neck squamous cell carcinoma. The study enrolls adults whose tumors express a speci…

This trial is testing whether a new drug called raludotatug deruxtecan (R-DXd), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer and delay cancer growth compared to standard chemotherapy. The study includes adults with high-grade serous or…

This trial is testing whether a special type of radiation called radscopal radiotherapy—which combines low-dose radiation to the main tumor and precise high-dose radiation to distant metastases—can enhance the effects of two immunotherapy drugs (sintilimab and ipilimumab) in peop…

This study tests whether an intestinal or multivisceral transplant can help people with a rare abdominal cancer called pseudomyxoma peritonei (PMP) that cannot be removed by surgery. Twenty participants will receive the transplant and be followed for 12 months to see if they surv…

This early-phase trial is testing whether combining two immune-based treatments—Sipuleucel-T, a vaccine made from a patient's own immune cells, and N-803, a drug that boosts immune activity—is safe and tolerable for men with metastatic prostate cancer that has stopped responding …

This early-stage trial tests an experimental oral drug called SNV1521, a PARP inhibitor, combined with the RAS-targeting medicine daraxonrasib in adults with pancreatic cancer that cannot be surgically removed or has spread. The main goals are to find safe and tolerable doses of …

This trial is testing an experimental drug called AMT-116 in people with advanced or metastatic non-squamous non-small cell lung cancer that has worsened after standard treatments. The study has two parts: the first compares two different doses of AMT-116 to see which works bette…

This pilot study will test whether a fish oil-enriched nutritional supplement, combined with weekly nutrition counseling, is feasible and safe for people with head and neck cancer undergoing chemoradiotherapy. Fifteen participants will start taking the supplement two weeks before…

This clinical trial is investigating whether an experimental drug called SHR-9839, when used alone or combined with standard chemotherapy and an immunotherapy drug, can help people with advanced esophageal squamous cell carcinoma. The study will include about 84 adults aged 18 to…

This trial is testing an experimental therapy called CRG-150, which uses a patient's own immune cells that have been gene-edited to potentially fight cancer. The study includes adults with advanced HR-positive/HER2-negative breast cancer, triple-negative breast cancer, or prostat…

This phase 3 trial is testing whether giving men with metastatic prostate cancer half the standard dose of certain hormone therapies (called ARPIs) can be just as effective as the full dose, while causing less fatigue and fewer treatment stoppages. About 1,500 men with prostate c…

This phase 2 trial is investigating whether adding an experimental drug called retlirafusp alfa to standard chemotherapy or to another drug called fuzuloparib can improve outcomes for people with triple-negative breast cancer (TNBC). The study includes two groups: one with early-…

This trial is testing whether adding an immunotherapy drug (PD-1 antibody) to standard treatment can improve outcomes for people with recurrent head and neck cancer. Participants will be randomly assigned to receive either the immunotherapy before and after surgery, or standard s…

This early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…

This trial is testing whether adding the immunotherapy drug finotonlimab to chemotherapy before and after surgery can improve outcomes for people with stage II head and neck squamous cell carcinoma. Participants will receive either standard treatment (surgery plus chemoradiothera…

This phase 2 trial tests whether the immunotherapy drug cemiplimab can be used alone before surgery for certain patients with early-stage non-small cell lung cancer (NSCLC) that can be removed. The goal is to see if some patients can safely skip chemotherapy and its harsh side ef…

This phase 2 trial is testing whether giving the immunotherapy drug penpulimab together with chemotherapy before surgery can help people with locally advanced hypopharyngeal carcinoma, a type of head and neck cancer. The study will include about 15 adults aged 18 to 80 with resec…

This phase II trial is testing whether an experimental drug called sacituzumab tirumotecan (Sac-TMT) can shrink tumors in people with thymic carcinoma that cannot be surgically removed and has already been treated with platinum-based chemotherapy. Participants receive the drug in…

This phase 2 trial tests whether adding a targeted chemo procedure (TACE) to standard immunotherapy can improve outcomes for people with unresectable liver cancer. About 90 participants will receive either atezolizumab/bevacizumab or durvalumab/tremelimumab plus TACE. The goal is…

This phase 3 trial tests whether the experimental drug mocertatug rezetecan (Mo-Rez), given alone or with bevacizumab, can delay cancer progression better than standard observation or bevacizumab alone in people with newly diagnosed advanced ovarian cancer that does not have a ho…

This trial is testing whether combining two targeted therapies—lorlatinib and sacituzumab tirumotecan—can better control advanced ALK-positive non-small cell lung cancer when used as the first treatment. The study involves about 153 adults with locally advanced or metastatic dise…

This early study tests a new drug (177Lu-DTPA-SC16.56) that delivers radiation directly to cancer cells in people with small-cell lung cancer or neuroendocrine prostate cancer that has come back after standard chemotherapy. The main goal is to find the safest dose and see if the …

This phase II trial tests whether choosing chemotherapy based on a specific gene mutation (SMAD4) can improve outcomes for people with pancreatic cancer that is or may be surgically removable. The SMAD4 gene normally acts as a brake on tumor growth, but when it's mutated, tumors …

This phase 2 trial is testing whether combining an experimental immunotherapy (SHR-1701) with a targeted therapy (apatinib) can shrink tumors in people with advanced liver cancer that has progressed after initial treatment. About 80 adults with unresectable or metastatic hepatoce…

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This phase 2 trial tests giving short course radiation therapy along with standard chemotherapy before surgery for stomach cancer. The goal is to see if this total neoadjuvant therapy leads to a higher rate of complete cancer disappearance, with fewer side effects than traditiona…

This trial asks whether some people with intermediate-risk bladder cancer can safely skip chemotherapy after having their tumor removed. Doctors will use a urine test before surgery to find patients whose tumors are unlikely to shed detectable signals. These patients will then be…

This trial tests the drug mercaptopurine in people with hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare genetic condition that raises the risk of skin, uterine, and kidney tumors. The study aims to find the safest dose and see if the drug can shrink kidney canc…

This early-stage trial is testing an experimental drug called JNJ-98768111 in people with advanced prostate cancer that has spread to other parts of the body. The drug is designed to seek out and attach to a protein called KLK2 on prostate cancer cells, delivering a toxic agent d…

This trial is testing whether a combination of drugs—inavolisib plus fulvestrant, with or without palbociclib—is safe for people with a specific type of advanced breast cancer (HR+, HER2-negative) that has a PIK3CA mutation, and who also have type 2 diabetes. The main focus is on…

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This study offers continued access to an experimental combination of two oral drugs—avutometinib and defactinib—for people with recurrent low-grade serous ovarian cancer (LGSOC) who have already been benefiting from this treatment in a prior study. The goal is to allow uninterrup…

This phase 3 trial tests whether a combination of sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) works better than standard chemotherapy before surgery for stage II-III triple-negative breast cancer. About 765 participants will be enrolled. The study aims to improv…

This phase 3 trial is testing whether giving four cycles of chemotherapy combined with targeted therapy (trastuzumab and pertuzumab) before surgery works as well as the standard six cycles for people with intermediate-risk HER2-positive breast cancer. The goal is to see if a shor…

This phase 2 trial tests whether adding MRG003 (a targeted drug) to toripalimab (an immunotherapy) before surgery can shrink tumors more than toripalimab alone in people with PD-L1-positive, locally advanced head and neck cancer. Participants receive two cycles of either the comb…

This study tests a combination of two experimental drugs, obrixtamig and ZL-1310, designed to help the immune system fight cancer. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers. The trial has two parts: the first finds a safe dose of the tw…

This study looks at three ways to treat subcapsular hepatocellular carcinoma (HCC), a type of liver cancer near the surface of the liver. It compares two minimally invasive microwave ablation methods—one that avoids piercing the tumor and one that does—against traditional surgica…

This Phase II trial will test whether adding a live biotherapeutic product called MO-03 (a type of probiotic) to standard chemotherapy and the immunotherapy drug pembrolizumab can improve outcomes for 50 people with early-stage triple-negative breast cancer. Participants will tak…

This phase 3 trial is testing whether giving targeted therapies that match specific genetic abnormalities in a person's tumor can delay or prevent biliary tract cancer from coming back after surgery. Participants will have their tumor tested for certain markers, and if found, the…

This trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunother…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This phase 2 trial is testing whether adding an investigational drug called ivonescimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. Ivonescimab is a bispecific antibody that works in two ways: it helps the immune sys…

This study compares a robotic water-jet procedure called Aquablation to active surveillance (close monitoring) in 333 men with low- or intermediate-risk localized prostate cancer. The goal is to see if Aquablation can better prevent cancer from progressing to a more serious grade…

This phase 2 trial is testing whether adding anlotinib to a combination of culmerciclib and endocrine therapy can control disease in people with HR-positive, HER2-negative breast cancer that has spread to the brain. The study enrolls adults with newly diagnosed or progressing bra…

This phase 2 trial is testing a novel combination for people with metastatic pancreatic cancer that has progressed after standard first-line chemotherapy. The approach combines a device that alternately freezes and heats the tumor (multimodal thermal therapy) with a personalized …

This trial tests whether a special light mode called linked color imaging (LCI) helps doctors find more sessile serrated lesions (a type of precancerous colon polyp) during colonoscopy than standard white light. About 2,000 adults aged 45 and older having their first screening co…

This trial is testing whether an experimental drug called MRG007, given together with standard chemotherapy and targeted therapies, can safely shrink tumors in people with advanced colorectal cancer that cannot be removed by surgery. The study involves about 316 participants and …

This early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …

This trial tests whether a newer surgical method called en bloc resection, which removes bladder tumors in one piece, works better than the standard piecemeal approach for people with intermediate- or high-risk non-muscle-invasive bladder cancer. All participants also receive a y…

This trial explores whether people with early-stage triple-negative breast cancer and high levels of tumor-infiltrating lymphocytes (TILs) can safely skip a class of chemotherapy drugs called anthracyclines, which are effective but can harm the heart. Participants receive 12 week…

This study tests a new drug, prifetrastat, combined with fulvestrant for people with advanced HR+/HER2- breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. About 51 participants will receive the combination to see if it can shrink tumors o…

This phase II trial is testing whether combining an experimental drug called ALK201 with an existing immunotherapy, ivonescimab, can help people with advanced squamous non-small cell lung cancer. The study includes adults whose tumors have a specific marker (FGFR2b) and who have …

This trial tests whether a minimally invasive procedure called bronchoscopic microwave ablation can be as effective as surgery for early-stage lung cancer (stage IA). The procedure uses a bronchoscope to guide a needle to the tumor and destroy it with heat, potentially preserving…

This phase 2 trial is testing whether the drug ivonescimab can help control advanced or metastatic adrenal cancers, specifically adrenocortical carcinoma (ACC) and pheochromocytoma/paraganglioma (PPGL), that have not responded to prior treatment. About 20 adults with these rare c…

This trial is testing whether giving two drugs—sintilimab and disitamab vedotin—before surgery can shrink tumors in people with a rare type of eyelid cancer called sebaceous gland carcinoma. Participants receive two cycles of the combination, then undergo surgery to remove the tu…

This trial is testing whether giving a combination of an experimental immunotherapy (epalolitoworelimab) and a targeted therapy (lenvatinib) before and after surgery can improve outcomes for people with high-risk clear cell kidney cancer. The treatment is given first to shrink th…

This phase 2 trial tests whether alternating two targeted chemotherapy drugs—sacituzumab govitecan and trastuzumab deruxtecan—can help people with HER2-low triple-negative breast cancer that has spread. About 260 participants will be randomly assigned to receive either the altern…

This phase 2 trial is testing whether combining two drugs—mirvetuximab soravtansine and suvemcitug—can help people with a type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The study will enroll 20 adults with FRα-positive, platinum-resistant recur…

This study looks at a new treatment for people with a specific type of advanced stomach cancer (HER2-positive) that has stopped responding to standard therapies. It combines a targeted drug (disitamab vedotin) with immunotherapy and a special type of radiation. The goal is to see…

This trial is testing an experimental drug called DS-3939a in adults with advanced solid tumors, including a type of lung cancer. The study has two parts: the first checks safety and the best dose, and the second looks at whether the drug, alone or with other cancer treatments, c…

This trial is testing whether a new experimental drug called YL201, when combined with the immunotherapy serplulimab, can help people with extensive-stage small cell lung cancer live longer compared to the current standard treatment (carboplatin and etoposide plus serplulimab). T…

This trial is testing whether giving radiotherapy to the main lung tumour, in addition to standard chemotherapy or immunotherapy, can reduce cancer spread and help people with metastatic non-small-cell lung cancer live longer. Around 420 adults with newly diagnosed stage IV lung …

This early-stage trial is testing an experimental treatment called the IKS04 regimen in people with advanced cancers of the digestive system, including colorectal, stomach, pancreatic, and bile duct cancers. The regimen combines a targeted antibody-drug conjugate with an addition…

This trial is investigating whether a new combination of drugs—BL-B01D1 plus a PD-1/VEGF bispecific antibody—can work better than the current standard treatment (tislelizumab plus chemotherapy) for people with locally advanced or metastatic non-squamous non-small cell lung cancer…

This trial is testing an experimental drug called GB268, a tri-specific antibody that targets three key pathways involved in cancer growth. It is being studied alone or in combination with other treatments in people with locally advanced or metastatic breast cancer. The goal is t…

This trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy that targets PD-1 and VEGF, works better than standard chemotherapy combined with the same immunotherapy for people with advanced squamous non-small cell lung cancer. About 200 adults with th…

This study follows young women with hormone-sensitive breast cancer who stayed premenopausal or resumed menstruation after chemotherapy. Researchers are investigating whether adding two years of ovarian function suppression to standard tamoxifen therapy can lower the chance of ca…

This clinical trial is testing whether adding two newer drugs—QL1706 and lenvatinib—to standard chemotherapy can help people with a rare and aggressive cancer called extrapulmonary neuroendocrine carcinoma (EP-NEC). The study will compare the combination against chemotherapy alon…

This trial is testing whether adding elemene liposomes—a compound derived from a traditional Chinese medicinal plant—to standard chemotherapy (carboplatin and paclitaxel) can help people with advanced or recurrent endometrial cancer. Participants will receive either the combinati…

This trial is testing whether a new oral drug called HRS-2329, which blocks multiple RAS proteins, can shrink tumors or slow disease when combined with other anti-cancer therapies. It is enrolling adults with advanced pancreatic cancer that has RAS mutations or amplifications and…

This early-stage trial is testing an experimental drug called SHR-6914 in men with prostate cancer that has spread to other parts of the body. The main goal is to see if the drug is safe and tolerable, and to find the right dose for future studies. Participants must have a confir…

This trial is testing whether a combination of two newer drugs—envafolimab and suvemcitug—plus chemotherapy delivered directly to the liver can shrink advanced liver tumors enough to allow surgery. The study enrolls adults aged 18–75 with liver cancer that is currently too advanc…

This trial is testing whether using microultrasound to guide a radiation boost to cancerous spots inside the prostate can reduce side effects compared to standard radiation therapy. Men with intermediate-risk prostate cancer will receive stereotactic body radiation therapy (SBRT)…

This phase II trial is testing whether adding an immunotherapy drug (serplulimab) and a targeted antibody (bevacizumab) to standard chemotherapy can help people with metastatic pancreatic cancer that has progressed after initial treatment. The study enrolls about 34 adults whose …

This phase 3 trial tests whether giving radiation therapy early — before symptoms appear — can reduce the risk of bone complications (like fractures or spinal cord pressure) in people with solid tumors that have spread to the bone. Participants have bone lesions that are consider…

This early trial is testing an experimental cell therapy called cCTL-GL01 in people with advanced stomach, esophageal, colon, or rectal cancers that have not responded to standard treatments. The therapy uses a patient's own immune cells, which are specially trained in the lab to…

This trial tests whether an artificial intelligence system can tailor the timing of follow-up scans for people who have had liver cancer surgically removed or ablated. Instead of fixed-interval scans every four months, the AI uses routine clinical data to estimate each person's c…

This trial tests whether a wireless wearable monitor (chest patch or wristband) plus a smartphone-based rehab program can help people recover lung function after surgery for non-small cell lung cancer. Participants who have had curative-intent surgery will either receive standard…

This trial investigates whether ebastine, a widely used allergy medication, can reduce the risk of liver cancer returning after surgery. The study enrolls people with a specific high-risk tumor feature called tumor budding. All participants will take ebastine daily for a year, an…

This phase 2 trial is testing whether giving the immunotherapy drug tislelizumab every 2 weeks or every 4 weeks, alongside standard chemotherapy, is safe and effective for Japanese patients with advanced esophageal cancer that cannot be removed by surgery. The study aims to find …

This trial tests whether adding darolutamide to standard chemotherapy and hormone therapy before prostate removal can improve long-term outcomes for men with locally advanced prostate cancer. Participants receive either the triple combination or the standard two-drug regimen for …

This phase III trial is testing whether a new drug called BL-B01D1, combined with an immunotherapy (PD-1 antibody), works better than standard chemotherapy plus immunotherapy for people with advanced triple-negative breast cancer that has a specific protein (PD-L1). The study inc…

This umbrella trial is testing whether assigning treatment based on a person's tumor genetics can improve outcomes for advanced biliary tract cancers. Participants receive one of several targeted therapies or immunotherapy, depending on their genetic test results. The study aims …

This early-stage trial tests whether an experimental drug called TLN-499, combined with the approved cancer drug venetoclax, is safe and tolerable for people with certain advanced solid tumors that have stopped responding to standard treatments. The study includes adults with sma…

This trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…

This trial is investigating whether an experimental drug called XNW5004, when combined with standard anti-tumor therapies, can help control advanced prostate cancer. The study involves men with prostate cancer that has spread. Researchers are looking at how safe the combination i…

This study looks at whether combining the targeted drug donafenib with an immunotherapy drug and a liver-directed procedure (either chemoembolization or infusion chemotherapy) can help people with unresectable hepatocellular carcinoma — liver cancer that cannot be removed by surg…

This phase II trial is testing whether adding an experimental drug called retlirafusp alfa to standard chemotherapy and bevacizumab, with or without a short course of radiotherapy, can shrink liver metastases from colorectal cancer enough to allow surgical removal. The study enro…

This phase 3 trial is testing whether adding an experimental drug called SHR-1501 to the standard BCG therapy can improve outcomes for people with a high-risk form of bladder cancer that has not spread into the muscle wall. Participants must have had all visible tumors removed be…

This trial is investigating whether adding the beta-blocker propranolol to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with resectable locally advanced gastric or gastroesophageal junction cancer. About 49 participants will receive the c…

This trial is testing a combination of three drugs—benmelstobart, anlotinib, and etoposide—as a first treatment for elderly patients (65 and older) or those too frail for standard intensive chemotherapy. The goal is to see if this platinum-free regimen can control the cancer and …

This trial explores whether semaglutide, a drug approved for weight management, can affect tumor biology when given for 3 to 6 months before prostate removal surgery. About 20 men with intermediate-risk localized prostate cancer and a BMI over 35 will receive weekly injections. R…

This trial investigates whether adding dapagliflozin—a drug typically used for diabetes—to standard first-line therapy can improve tumor response in people with advanced liver cancer that cannot be surgically removed and who also have metabolic syndrome. About 44 participants wil…

This trial tests whether an artificial intelligence (AI) system can help doctors select the best first-line immune checkpoint inhibitor (ICI) therapy for adults with unresectable hepatocellular carcinoma (HCC), a type of advanced liver cancer. About 1,800 participants across 26 h…

This trial tests whether an artificial intelligence system can help surgeons better see and remove bladder tumors during a standard procedure called TURBT. The AI analyzes the live video from the surgical camera and highlights suspicious areas and recommended cutting edges on the…

This phase 3 trial is testing whether adding two immune-boosting drugs, iparomlimab and tuvonralimab, to standard chemotherapy can help people with a specific type of metastatic colorectal cancer that has stopped responding to first-line treatment. The study includes about 270 ad…

This early-phase trial is testing an experimental antibody-drug conjugate called MC002 in adults with advanced solid tumors, such as esophageal or lung cancer, that have progressed after standard treatments. MC002 is designed to target a protein found on cancer cells and deliver …

This trial tests whether a combination of whole-body electromyostimulation (WB-EMS) — a technology that uses electrical impulses to make muscles contract — and nutritional therapy can help people with certain gastrointestinal cancers preserve muscle mass. Participants include tho…

This trial investigates whether adding neratinib, a drug that blocks HER2/3/4 proteins, to standard hormone therapy can improve disease control in people with metastatic ER+/HER2- breast cancer that has stopped responding to first-line endocrine therapy. Participants will receive…

This trial compares two treatments for early-stage lung cancer in patients who cannot have surgery: microwave ablation delivered through a bronchoscope versus standard stereotactic body radiotherapy. The goal is to see which approach better controls the tumor over two years, with…

This early-phase trial is testing a new biologic drug, UGN-501, for people whose non-muscle invasive bladder cancer has returned after previous treatment. The drug is given directly into the bladder through a catheter once a week for six weeks, with possible quarterly maintenance…

This phase 3 trial is testing whether adding a three-month course of FOLFOX4s chemotherapy after short-course radiotherapy improves outcomes compared to radiotherapy alone in adults aged 75 and older with locally advanced rectal cancer. The study aims to see if the combination ca…

This phase III trial is testing whether adding an experimental drug called LBL-024 to standard chemotherapy can help people with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC), a rare and aggressive cancer. Participants will receive either LBL-024 or a placebo alongsid…

This study tracks the safety and effectiveness of mirvetuximab soravtansine (MIRV), a drug that targets a protein called folate receptor alpha on cancer cells, in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. Researchers will observe 400 patients r…

This phase II trial is testing an experimental drug called SMP-656 in people with HER2-positive breast cancer that has spread or cannot be removed and has worsened after prior treatment with a specific type of antibody-drug conjugate. The study aims to see if SMP-656 can shrink t…

This phase 2 trial is testing whether combining an experimental drug called S-531011 with a precise radiation technique known as RadScopal can help control metastatic colorectal cancer that has not responded to prior treatments. The study enrolls about 30 adults with advanced dis…

This trial is investigating whether women with node-positive breast cancer whose lymph nodes are cancer-free after chemotherapy can safely receive less extensive radiation. Instead of radiating the entire lymph node region, the study compares standard radiation to a more targeted…

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

This phase 2 trial is testing whether adding two extra drugs—bevacizumab and sintilimab—to the usual combination of irinotecan and cetuximab can shrink tumors in people with advanced colorectal cancer that no longer responds to irinotecan. The study enrolls 160 adults with RAS wi…

This phase II trial is testing whether a vaccine called STEMVAC can help prevent triple-negative breast cancer from coming back after surgery. The vaccine targets proteins that cancer cells use to grow and spread, aiming to boost the immune system to destroy any remaining tumor c…

This phase 3 trial tests whether a single dose of SRG-514 (ketorolac), given directly into the area where a breast tumor is removed, can help prevent cancer from coming back. The study enrolls adults with stage II-III triple-negative breast cancer who are having breast-conserving…

This phase 2 trial tests an experimental drug called sacituzumab tirumotecan in people with two rare types of cancer: papillary renal carcinoma and less common forms of bladder cancer. The drug is given by IV every two weeks for up to three years. The main goal is to see how many…

This trial tests whether an online, personalized lifestyle program can help rural postmenopausal breast and endometrial cancer survivors lose weight and improve their health. Participants follow a tailored diet and aerobic exercise plan, with mobile health tools to track progress…

This early-phase trial is testing whether a personalized mRNA vaccine called NeoOVSV, given alongside standard chemotherapy and an immunotherapy drug, can safely help prevent ovarian cancer from returning after surgery. The vaccine is designed to train the immune system to recogn…

This phase 2 trial is testing whether a targeted antibody-drug conjugate called sacituzumab tirumotecan, given alone or together with the immunotherapy pembrolizumab, can shrink tumors in people with ovarian clear cell carcinoma that has returned after prior immunotherapy. The st…

This phase II trial tests a personalized approach for people with locally advanced esophageal cancer. After initial chemoimmunotherapy, patients whose tumors shrink well go straight to surgery, while those with less response receive additional radiotherapy before surgery. The goa…

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

This early-phase trial tests an experimental drug called XNW28012 in people with metastatic pancreatic cancer whose disease has worsened after at least one prior treatment. XNW28012 is an antibody-drug conjugate designed to seek out a protein called tissue factor on cancer cells …

This phase II trial tests whether sacituzumab tirumotecan, an antibody-drug conjugate that targets the TROP2 protein, can shrink tumors in people with advanced small bowel adenocarcinoma that has worsened after platinum-based chemotherapy. About 27 adults with this rare cancer wi…

This phase 2 trial is testing whether a combination of an antibody-drug conjugate (disitamab vedotin), an immunotherapy (toripalimab), and targeted radiation can improve outcomes for people with high-risk upper tract urothelial carcinoma. Participants receive the drug and immunot…

This trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…

This trial compares standard stereotactic ablative radiotherapy (SBRT) to a version that intentionally delivers higher radiation doses to the tumor (hotspots) in people with early-stage non-small cell lung cancer. The goal is to see if hotspots improve local tumor control without…

This phase 3 trial investigates whether adding platinum-based chemotherapy to the immunotherapy drug tislelizumab helps people with a specific type of advanced lung cancer live longer without the disease worsening. Participants have non-small cell lung cancer that has spread, sho…

This study looks at how effective the drug Pluvicto (177Lu-PSMA-617) is in treating men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. Researchers will analyze medical records from over 1,000 patients …

This study tests whether adding a new oral drug called fulvestaciclib to standard anti-HER2 and hormone therapy can help people with HR+/HER2+ advanced breast cancer live longer without their disease getting worse. Some participants receive the combo after initial chemotherapy, w…

This phase 3 trial tests whether monitoring tumor DNA in the blood (ctDNA) can help doctors switch hormone therapy earlier in people with ER+/HER2- metastatic breast cancer. Participants whose ctDNA levels rise—before any symptoms or scans show progression—are randomly assigned t…

This phase II trial tests whether adding an immunotherapy drug (retlirafusp alfa) and possibly a third drug (pertuzumab) to the targeted therapy trastuzumab rezetecan can completely eliminate tumors before surgery in people with locally advanced HER2-positive stomach or gastroeso…

This phase II pilot trial is testing a three-drug combination—radium-223, darolutamide, and standard hormone therapy—in men with high-volume metastatic hormone-sensitive prostate cancer. The goal is to see if adding radium-223 as maintenance therapy after initial treatment can im…

This Phase 3 trial tests whether an experimental drug called QLS31905, combined with chemotherapy (CAPOX), works better than the current immunotherapy drug sintilimab plus the same chemotherapy for people with advanced gastric or gastroesophageal junction cancer. The study includ…

This phase 2 trial tests whether combining the experimental drug tunlametinib with other targeted therapies can shrink tumors or slow cancer growth in people with metastatic colorectal cancer that has worsened after at least one prior treatment. Participants are grouped based on …

This early-phase trial tests an experimental drug, KGX105, in people with advanced solid tumors that have not responded to standard treatments. KGX105 is designed to activate immune T-cells specifically within the tumor, potentially reducing side effects. The study will assess sa…

This trial investigates whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help immunotherapy work better in people with advanced liver cancer. Participants receive either a real transplant via colonoscopy or a sham procedure, alongside standard imm…

This phase 2 trial tests an oral drug called zanzalintinib in people with metastatic pheochromocytoma or paraganglioma that cannot be surgically removed and is growing. The study measures how many participants see their tumors shrink or stop growing. All participants take the dru…

This phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…

This phase II trial tests a combination of two immunotherapies (ipilimumab and sintilimab) plus a targeted drug (lenvatinib) as a first treatment for people with a rare and aggressive form of kidney cancer called TFE3-rearranged renal cell carcinoma. The study enrolls about 66 pa…

This study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…

This phase Ib/II trial investigates whether combining three drugs—two immunotherapies (IBI310 and sintilimab) and a blood-vessel blocker (bevacizumab)—given before and after surgery can improve outcomes for people with resectable hepatocellular carcinoma (liver cancer). The study…

This trial compares two weight-loss approaches—daily calorie restriction versus 5:2 intermittent fasting—in people with small kidney tumors who are being monitored rather than treated immediately. The goal is to see which program helps patients lose more weight and whether that m…

This phase II trial tests an experimental drug called SYS6041, alone or combined with chemotherapy and other agents, in women whose ovarian cancer has returned. The study evaluates safety, the best dose, and how well the treatments shrink tumors. Participants must have a specific…

This study tests an experimental injection called BBM-C101 in 200 people with persistent HPV16 or HPV18 infection and low-grade precancerous lesions of the cervix, vulva, vagina, or anus. Participants receive four shots under the skin over three weeks. The trial monitors safety a…

This trial investigates whether combining two drugs—JS212 (given by IV) and JS111 (taken orally)—can safely and effectively shrink tumors in people with advanced non-small cell lung cancer that has a specific EGFR mutation. About 20 participants who have not had prior treatment f…

This trial tests whether adding orlistat, a weight-loss drug that blocks fat absorption, to standard progestin therapy can improve treatment response in young women (45 or younger) with early-stage endometrial cancer or atypical endometrial hyperplasia who have low progesterone r…

This trial investigates whether the immunotherapy drug cemiplimab can shrink advanced cutaneous squamous cell carcinoma in people who have received a kidney transplant. Because immunotherapy can trigger organ rejection, participants also receive the steroid prednisone to protect …

This study tests an experimental biologic, NWRD09, in women aged 18 to 65 with HPV16-positive cervical high-grade squamous intraepithelial lesions (HSIL), a precancerous condition. Participants receive four intramuscular injections over 12 weeks. The main goal is to see if the tr…

This trial investigates whether raising the body's core temperature to 41.5°C for 4 hours, called whole-body hyperthermia, can improve outcomes when added to standard chemotherapy for people with metastatic pancreatic cancer that has progressed after initial treatment. The study …

This study tests whether adding an experimental drug called retlirafusp alfa to standard chemotherapy can shrink advanced stomach or gastroesophageal junction cancers enough to allow complete surgical removal. Participants receive the drug combination before surgery, and those wh…

This phase 2 trial tests a new drug called ivonescimab (AK112) combined with chemotherapy (irinotecan and cisplatin) for people with metastatic digestive system neuroendocrine cancer that has spread. Some participants also receive a procedure called TACE, which blocks blood flow …

This study tests whether adding the experimental drug saruparib to standard hormone therapy can slow the growth of metastatic hormone-sensitive prostate cancer. It includes men whose cancer has not progressed after prior chemotherapy or a specific type of radiation therapy. Parti…

This study explores whether a simple blood test that measures tumor DNA (ctDNA) can help doctors decide when to stop a targeted radiation therapy called 177Lu-PSMA-617 in men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The goal is…

This phase 2 trial tests whether adding an experimental drug called ABSK043 to the standard targeted therapy osimertinib can help people with a specific type of advanced lung cancer (EGFR-mutated, PD-L1 positive). The study enrolls adults whose cancer has spread or cannot be surg…

This trial investigates a personalized approach for people with advanced EGFR-mutant non-small cell lung cancer who have not had prior treatment. Participants first take the targeted pill befotertinib for three weeks, then a blood test checks for minimal residual disease (MRD). T…

This phase 2 trial tests whether adding ivonescimab—a drug that blocks both PD-1 and VEGF—to standard chemoradiotherapy improves outcomes for people with high-risk nasopharyngeal carcinoma. The study enrolls adults aged 18–65 with previously untreated stage T3N2M0 or stage III di…

This trial investigates whether giving liver cancer patients infusions of their own immune cells, called cytokine-induced killer (CIK) cells, after surgery is safe and feasible. The cells are collected from the patient's blood, grown in a lab, and then returned through six intrav…

This phase III trial compares a shorter course of radiation therapy (hypofractionated) against the standard longer course for people with cervical cancer. Both groups also receive chemotherapy and brachytherapy. The goal is to see if the shorter schedule controls the cancer just …

This phase 3 trial tests an experimental drug called SYS6043 against standard chemotherapy in people with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. Participants are randomly assigned to receive either SYS6043 or one of three standard chemotherapies…

This phase II trial tests a combination of three drugs—Becotatug Vedotin, Tislelizumab, and low-dose Lenvatinib—in people with advanced esophageal squamous cell carcinoma whose cancer has progressed after first-line therapy. The study aims to see if this triple therapy can shrink…

This trial compares how well patients tolerate dalpiciclib versus abemaciclib or ribociclib when each is combined with standard hormone therapy for high-risk HR+/HER2- early breast cancer. About 456 patients who have completed initial local treatment will be randomly assigned to …

This study tests whether giving a combination of two drugs (becotatug vedotin and putlimab) before surgery, followed by radiotherapy and more putlimab after surgery, can improve outcomes for people with locally advanced head and neck cancer. The trial enrolls about 35 participant…

This clinical trial is testing a shorter, more intense course of radiation therapy (called hypofractionated radiotherapy) for people who have had surgery for thymic epithelial tumors, including thymoma and thymic carcinoma. The goal is to see if this approach can keep the tumor f…

This trial investigates whether tailoring treatment based on specific biomarkers can improve outcomes for people with advanced esophageal squamous cell carcinoma that has spread. Participants are randomly assigned to receive either standard chemotherapy plus a PD-1 inhibitor or t…

This pilot trial tests whether adding the drug alisertib to usual care can help people with advanced HR+/HER2+ breast cancer whose disease has become resistant to standard treatments. Researchers want to see if alisertib can block communication between hormone receptors and HER2,…

This early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…

This phase 3 trial tests whether a new drug called mocertatug rezetecan (Mo-Rez) combined with bevacizumab works better than standard chemotherapy plus bevacizumab for women with platinum-sensitive ovarian cancer. The study includes about 690 participants whose cancer has returne…

This phase II trial investigates whether combining the immunotherapy adebelizumab with other anti-tumor drugs, given before and after surgery, can improve outcomes for people with resectable non-small cell lung cancer. The study enrolls adults aged 18-70 with stage II or IIIA dis…

This phase 3 trial tests whether adding an experimental drug (GSK5733584) to standard immunotherapy can help keep advanced or recurrent endometrial cancer from growing. About 610 adults who have already completed initial chemotherapy with immunotherapy will receive either the new…

This trial is studying a combination of two targeted drugs, patritumab deruxtecan and trastuzumab deruxtecan, for people with a specific type of advanced breast cancer that is hormone receptor positive and has low or ultra-low levels of a protein called HER2. The study aims to fi…

This phase II trial tests a new drug called SKB500 in combination with standard chemotherapy and immunotherapy for people with advanced esophageal squamous cell carcinoma that cannot be removed by surgery. The study will evaluate how well the combination shrinks tumors and how sa…

This study tests a procedure that uses a thin needle guided by an endoscope to inject alcohol into a benign adrenal tumor that produces too much aldosterone, a hormone that raises blood pressure. The goal is to destroy the tumor without surgery. The trial enrolls 30 adults with l…

This trial tests an experimental vaccine called SYS6026 in people with high-grade cervical lesions caused by HPV type 16 or 18. The goal is to see if the vaccine can help the body clear the virus and reverse the lesions, potentially avoiding the need for surgery. Participants are…

This trial tests whether adding a personalized, ultra-precise radiation technique called PULSAR to standard chemotherapy and immunotherapy is safe for people with esophageal or gastro-esophageal junction cancer. The study aims to find the best radiation dose that can be given wit…

This phase 2 trial tests an experimental drug called SHR-A1904 in people with advanced colorectal cancer that has spread and no longer responds to standard treatments. The study aims to see if the drug is safe and can shrink tumors or slow the disease. Participants must have alre…

This clinical trial tests a new approach for people with a type of bile duct cancer that cannot be removed by surgery. It compares a combination of targeted therapy and a procedure that delivers chemotherapy directly to the liver against standard chemotherapy. The goal is to see …

This study tests whether a 12-week virtual cooking and nutrition program is practical and helpful for Hispanic prostate cancer survivors and their caregivers. Participants attend nutrition education, cooking classes, and health coaching sessions online. The goal is to see if the …

This study tests an experimental drug called HSK41959, taken as a tablet, in combination with standard cancer treatments for people with advanced solid tumors that lack a gene called MTAP. The trial includes patients with non-small cell lung cancer, pancreatic cancer, and other a…

This phase II trial tests a combination of two drugs—sacituzumab tirumotecan (a targeted chemotherapy) and tagitanlimab (an immunotherapy)—as a second-line treatment for people with advanced esophageal squamous cell carcinoma or gastric/gastroesophageal junction adenocarcinoma. T…

This phase 3 trial tests whether adding an experimental drug called cadonilimab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. Cadonilimab is a bispecific antibody that targets two immune checkpoints (PD-1 and CTLA-4) …

This study investigates whether adding isunakinra, a modified protein that blocks inflammation, can make triple-negative breast cancer more sensitive to standard immunotherapy and chemotherapy. The trial enrolls adults with newly diagnosed, locally advanced triple-negative breast…

This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…

This phase 2 trial tests whether combining the immunotherapy drug toripalimab with a specific chemotherapy regimen can shrink tumors in people with advanced small cell lung cancer that has progressed after prior treatments. Participants receive toripalimab plus a rotating schedul…

This study tests whether a daily oral supplement containing green tea extract (EGCG), folic acid, vitamin B12, and hyaluronic acid can help women clear a persistent human papillomavirus (HPV) infection. HPV is a common virus that can cause cervical cancer if it stays in the body …

This phase 3 trial compares two surgical approaches for early-stage non-small cell lung cancer with small (≤2 cm), solid-dominant tumors located deep within the lung. One group receives segmentectomy, which removes only the affected segment of the lung, while the other receives l…

This phase 2 trial is testing whether giving platinum-based chemotherapy (carboplatin and etoposide) together with the immunotherapy tarlatamab can help patients with advanced small-cell lung cancer whose disease has worsened while on tarlatamab alone. The study enrolls about 54 …

This study tests a new approach called photoimmunotherapy for people with locally advanced or borderline resectable pancreatic cancer. Patients receive an injection of ASP-1929, a drug that attaches to cancer cells and becomes active when exposed to a specific light. During surge…

This study looks at how well the chemotherapy drug temozolomide works for people with aggressive pituitary tumors or pituitary cancer that hasn't responded to standard treatments like surgery or radiation. Researchers are collecting data from medical records across multiple hospi…

This study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…

This trial tests a new drug called becotatug vedotin, given together with standard chemotherapy (cisplatin) and radiation, for people with a type of advanced esophageal cancer. The main goals are to find the safest dose and see how well the combination works. About 12 participant…

This trial tests whether a new skin graft substitute (CAMP) plus standard wound care helps wounds heal faster after Mohs surgery for skin cancer compared to standard care alone. About 160 adults who have had Mohs surgery for a skin cancer will be randomly assigned to receive eith…

This trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …

This observational study follows about 196 adults with early-stage (pT1) rectal cancer who have high-risk features after local tumor removal. Instead of undergoing radical surgery that often requires a colostomy, participants receive adjuvant radiotherapy or chemoradiotherapy. Th…

This phase 2 trial tests the drug inavolisib in people with pancreatic ductal adenocarcinoma whose cancer has worsened after prior chemotherapy. The study aims to see if inavolisib can shrink tumors or slow disease progression. Participants take inavolisib daily by mouth, and the…

This phase 2 trial tests whether giving a combination of an immunotherapy drug (serplulimab), an epigenetic drug (decitabine), and chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced colorectal cancer. The study enrolls 35 adults with previou…

This trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…

This trial tests whether adding a Chinese herbal formula called Shuganhuazhuo to standard anti-cancer therapy can improve liver function and survival in people with advanced hepatocellular carcinoma (the most common type of liver cancer). The study includes 120 adults who are abo…

This trial investigates whether combining two drugs—trastuzumab deruxtecan (T-DXd) and cetuximab—can shrink tumors in people with advanced colorectal cancer that has low levels of the HER2 protein and has worsened after standard treatments. The study enrolls adults with metastati…

This phase 2 trial tests whether adding the experimental drug HRS-4642 to standard chemotherapy, with or without the immunotherapy adebrelimab, can shrink pancreatic tumors before surgery. The study enrolls adults aged 18-70 with pancreatic ductal adenocarcinoma who have at least…

This phase 3 trial tests whether adding three drugs—SHR-8068, adebrelimab, and bevacizumab—to a standard liver-directed procedure (TACE) can better control incurable hepatocellular carcinoma. About 690 adults with liver cancer that cannot be surgically removed will receive either…

This phase 2 trial tests a combination of two drugs—becotatugvedotin (a targeted therapy that delivers a toxin directly to cancer cells) and pucotenlimab (an immunotherapy that helps the immune system attack cancer)—as a second-line treatment for people with advanced gastric or g…

This trial tests a follow-up strategy for people with nasopharyngeal cancer that has spread to neck lymph nodes (N3) after radiation therapy. Participants are assigned to standard follow-up or an enhanced approach that uses advanced imaging and a blood test (EBV DNA) to decide if…

This phase 2 trial is testing whether a combination of two drugs—zanzalintinib (a pill taken daily) and pembrolizumab (given by IV every three weeks)—can shrink advanced kidney tumors before surgery and help prevent the cancer from coming back afterward. The study enrolls people …

This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan (Sac-TMT) and fruquintinib—as a second-line treatment for people with advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after initial therapy. The study enrolls about 45 par…

This trial tests an experimental drug called SYH2095, taken as a daily pill, in people with advanced solid tumors that have no effective standard treatment. The drug blocks a protein (KAT6A/B) involved in cancer cell growth. The study aims to find a safe dose and check for early …

This trial tests a combination of two drugs—tislelizumab and SYS6010—in people with advanced non-small cell lung cancer (NSCLC) whose cancer has progressed after immunotherapy. Tislelizumab is an approved immunotherapy, and SYS6010 is an experimental drug that targets EGFR on can…

This phase III trial compares the immunotherapy drug pembrolizumab to active surveillance (no treatment) after kidney cancer surgery in patients with non-clear cell renal cell carcinoma, a less common type of kidney cancer. The goal is to see if pembrolizumab can help the immune …

This study tests a personalized approach for people with muscle-invasive bladder cancer who are scheduled for bladder removal surgery. Before treatment, a small sample of the tumor is used to grow cell clusters in the lab. These clusters are tested against different drugs to find…

This phase III trial is testing whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy after short-course radiation can improve outcomes for people with a specific type of locally advanced rectal cancer (pMMR/MSS). Participants receive eith…

This study tests whether a combination of three drugs—kumorixilib, capecitabine, and letrozole—given before surgery can slow or shrink tumors in people with HR-positive, HER2-negative breast cancer. Participants take the drugs for six 28-day cycles, then have surgery. The main go…

This trial tests a new drug called DN022150 in people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. Participants have already received at least one prior treatment. The study compares DN022150 alone against standard chemotherapy options to s…

This early-phase trial tests whether adding mild heat therapy (thermotherapy) to standard chemoradiation is safe and tolerable for people with advanced head and neck cancer. The heat, applied once a week, aims to make the cancer more sensitive to treatment. The study includes two…

This trial investigates whether a combination of two immunotherapy drugs, nivolumab and ipilimumab, can control advanced liver cancer in patients with moderate cirrhosis (Child-Pugh B). The dosing is adjusted based on how each patient responds. The study aims to see how many pati…

This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan and an immune checkpoint inhibitor—in people with recurrent or metastatic head and neck squamous cell carcinoma that has progressed after standard therapy. The goal is to see if the combination can shrink…

This clinical trial is testing a combination of two experimental drugs, IMM2510 and IMM27M, in people with advanced hepatocellular carcinoma (a type of liver cancer) who have not yet received treatment for their advanced disease. The drugs are designed to help the immune system r…

This study tests a smartphone app called DinSkoliose, designed to help adolescents with idiopathic scoliosis stick to their treatment plan. The app includes features like reminders for brace wear and exercises, symptom tracking, and educational content. Thirty teens will use the …

This study monitors the safety and effectiveness of mirvetuximab soravtansine (MIRV) in people with a specific type of ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy and tests positive for the folate receptor-alpha…

This phase 2 trial tests a single drug called PD-1/IL-2α-bias bispecific antibody fusion protein in people with advanced or metastatic esophageal squamous cell carcinoma whose cancer worsened after prior immunotherapy and chemotherapy. The drug is designed to boost the immune sys…

This study tests a new drug called XTX501 in people with metastatic non-small cell lung cancer (NSCLC) or other advanced solid tumors. The goal is to see if the drug is safe and can shrink tumors. Participants receive XTX501 alone, and researchers monitor side effects and how wel…

This study looks at how well third-generation EGFR-targeted drugs work as follow-up treatment after surgery for people with early-stage non-small cell lung cancer that has certain high-risk features. Researchers will observe about 500 patients in China who have EGFR mutations and…

This early-stage trial tests whether a personalized vaccine, made from each patient's unique tumor mutations, can safely boost the effects of the immunotherapy drug pembrolizumab in people with advanced kidney cancer. The vaccine is designed to train the immune system to recogniz…

This trial investigates whether surgically removing the primary breast tumor, followed by standard systemic therapy, improves survival compared to systemic therapy alone in women with stage IV breast cancer that has spread only to a single bone site. The study enrolls women aged …

This study tests an experimental drug, TAX2, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in more people. Researchers will monitor side effects, h…

This phase 2 trial tests the drug zanzalintinib in people whose adenoid cystic carcinoma (a rare salivary gland cancer) has returned or spread. Despite initial surgery and radiation, about half of patients experience recurrence, and current treatments offer limited benefit. Parti…

This trial compares two techniques—snare tip soft coagulation and hybrid APC—used to burn the edges of the wound after removing large colon polyps. The goal is to see which method is faster while still preventing polyps from coming back. About 140 adults with large non-cancerous …

This study tests whether two common heart medications—atorvastatin (a statin) and lisinopril (an ACE inhibitor)—can prevent or reduce heart damage caused by radiation therapy for chest cancers like breast, lung, and esophageal cancer. About 60 adults receiving chest radiation wil…

This study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…

This early-stage trial tests an experimental imaging agent called 68Ga-NYM096 in 20 adults who have a kidney mass of uncertain nature seen on CT or MRI and are scheduled for surgery. The agent is designed to attach to a protein common on clear cell renal cell carcinoma cells, pot…

This trial asks whether adding artificial intelligence (AI) to radiologists' reading of liver CT scans can match or improve standard reporting. It involves 40,000 adults who had contrast-enhanced CT scans of the abdomen. On some days, radiologists first read scans on their own, t…

This trial investigates whether a special PET imaging tracer called [18F]FTT can help predict how well people with newly diagnosed bile duct cancer (cholangiocarcinoma) will respond to standard chemotherapy. The tracer binds to a protein called PARP1, which some tumor cells produ…

This pilot study investigates whether a PSMA PET scan, using an injected radiotracer, can detect clinically significant prostate cancer recurrence one year after focal HIFU treatment, compared with the standard MRI. About 30 men with prostate cancer who meet specific criteria wil…

This early study tests a new radioactive antibody called NTH-2403 in 16 people with advanced colorectal, head and neck, lung, or triple-negative breast cancers. The antibody targets a protein found on cancer cells and their supporting cells, allowing doctors to see tumors on scan…

This trial tests whether a specialized ultrasound catheter, normally used in heart arteries, can be safely threaded into the upper urinary tract to measure how deeply a tumor has invaded the wall. Fifteen adults with upper tract urothelial carcinoma who are already scheduled for …

This pilot study is testing whether a special PET/MRI scan using a radioactive tracer called 68Ga-PSMA-11 can better identify all areas of significant prostate cancer in men with localized disease. The goal is to improve selection for focal therapy, a treatment that targets only …

This trial tests whether two imaging agents, Panitumumab-IRDye800 and [18F]NOTA-ABY-030, are safe and useful for helping surgeons identify head and neck tumors and cancer-containing lymph nodes during surgery. Adults with head and neck squamous cell carcinoma who are scheduled fo…

This trial tests whether an AI system called GI Genius can help doctors accurately tell apart small colorectal polyps (5 mm or less) during a colonoscopy—identifying which ones are harmless versus those that need monitoring. For each small polyp, doctors first record their own di…

This trial tests whether a fluorescent dye called zopocianine can make prostate cancer cells glow under near-infrared light during surgery. Men with prostate cancer scheduled for prostatectomy receive a single dose of the dye before surgery. The goal is to see if the dye helps su…

This trial is testing whether a breath analysis device can detect unique chemical patterns—called volatile organic compounds—that may signal the presence of cancer. Researchers will collect breath samples from 1,000 people with various cancers and 1,000 healthy volunteers, then u…

This trial explores whether betacyanin, a pigment found in beetroot, can help doctors detect anastomotic leakage — a serious complication where intestinal contents leak after rectal cancer surgery — earlier than current methods. About 120 people undergoing laparoscopic rectal can…

This trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…

This pilot study tests whether a structured case-finding pathway can help detect pancreatic cancer earlier in Swiss primary care. Adults aged 60 or older with warning signs like new-onset diabetes, unexplained weight loss, or a family history of pancreatic cancer are invited to u…

This trial is testing whether a special PET scan (FTT-PET) and a blood test that looks for tumor DNA (ctDNA) can predict how well men with metastatic prostate cancer will respond to PARP inhibitor therapy. The study will enroll about 75 men whose cancers have certain genetic muta…

This study is testing a simple breath test to help detect gastrointestinal cancers—including cancers of the esophagus, stomach, pancreas, liver, and bowel—at an earlier stage. The test measures tiny molecules in exhaled breath that may be linked to these cancers. Participants pro…

This study is developing an artificial intelligence (AI) system that can analyze standard MRI brain scans to determine the specific molecular subtype of a child's brain tumor before surgery. The research includes 1,400 children under 18 with suspected brain tumors, using both pas…

This pilot study is testing whether an artificial intelligence-assisted catheter camera system, called Uro-Cam, can safely and accurately detect bladder cancer. Adults with blood in their urine, abnormal urine cytology, or a history of non-muscle-invasive bladder cancer will unde…

This study compares two imaging methods for checking blood flow to the bowel during colorectal surgery: the standard technique using a dye called indocyanine green (ICG) and a newer dye-free method called Laser Speckle Contrast Imaging (LSCI). About 30 adults having elective colo…

This study tests a new ultrasound method called super-resolution ultrasound (SRUS) to see tiny blood vessels in liver tumors. Current scans show only larger vessels, but SRUS can detect vessels as small as 20 micrometers. Researchers will compare blood flow patterns in different …

This study aims to find molecular clues that could predict whether certain pancreatic growths will turn into cancer. Researchers will analyze tissue from patients having pancreatic surgery, using advanced genetic and protein tests on both the original tissue and lab-grown 3D cell…

This study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …

This pilot study explores whether a breath sample collected with the VosCryo device can provide enough cellular material to help diagnose advanced lung cancer. Researchers will compare breath samples from 12 people with late-stage lung cancer and 12 healthy relatives to see if th…

This study evaluates several experimental blood tests designed to detect ovarian cancer earlier. Researchers compare results from people with ovarian cancer to those without cancer to see how well the tests distinguish between the two. The tests look for specific changes in the b…

This study explores whether analyzing tumor DNA in cerebrospinal fluid can help doctors make better treatment decisions for people with malignant brain tumors or brain metastases from lung or breast cancer. Participants undergo a standard spinal tap or fluid collection, and the f…

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

This study tests whether taking low-dose aspirin can lower inflammation in the womb lining and help prevent endometrial cancer. It involves 25 postmenopausal women who have non-atrophic endometrial changes and pain. Participants will be randomly assigned to take aspirin or not, a…

This pilot study aims to see if offering self-collection kits for cervical cancer screening and HPV vaccination in emergency departments can reach women who have limited healthcare access. Researchers will enroll 100 women aged 18-65 and track how many participate and complete th…

This early-stage trial tests whether a daily supplement called SAMe can help prevent colorectal polyps (precursors to colon cancer) in 18 adults who have already had surgery for early-stage colon cancer. Participants will take SAMe for up to a year while researchers monitor for s…

This study follows women who previously received either one or two doses of the Gardasil9 HPV vaccine to see how long protection against HPV infection lasts. Researchers will check for persistent infections with HPV types linked to cancer. The goal is to understand if fewer doses…

This early-phase trial tests whether a device that blocks signals from the vagus nerve can safely help patients with metastatic pancreatic cancer who are experiencing severe weight loss (cachexia). The device is placed on the skin over the nerve and is used alongside chemotherapy…

This trial tests whether a mobile app that encourages social sharing and peer interaction can reduce anxiety and depression in people with head and neck cancer undergoing radiotherapy. Half of the 120 participants will use the app for eight weeks, while the other half receives a …

This study is for people with HPV-related oropharyngeal (throat) cancer, which often responds well to treatment. The goal is to see if lowering the radiation dose to certain areas can reduce side effects like dry mouth without hurting the chance of curing the cancer. About 132 pa…

This pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…

This study tests a 6-session telehealth program called STRIDE, which uses cognitive behavioral therapy to help women with hormone-positive breast cancer manage side effects from adjuvant endocrine therapy. Participants will be randomly assigned to either the STRIDE program or usu…

This study tests whether adding estrogen to standard prostate cancer treatment can improve quality of life for 60 men with metastatic hormone-sensitive prostate cancer. Standard therapy often causes hot flashes and other side effects by lowering estrogen. The study compares estro…

This study tests a virtual group lifestyle program for women with metastatic breast cancer. The goal is to see if more support helps them stick with healthy habits like diet and exercise. One hundred women will take part, and researchers will track safety and how well they follow…

This phase 2 trial tests whether a low dose of naltrexone (LDN) can reduce fatigue in men with prostate cancer who are on hormone therapy (ADT). The study will enroll 60 participants and measure fatigue, quality of life, and safety. It is not yet recruiting.

This study tests a LINE chatbot that gives visual, interactive tips to help lung cancer patients handle side effects from their targeted therapy. About 178 adults with advanced lung cancer will either get usual care or also access the chatbot. The goal is to see if the chatbot bo…

This trial tests whether a home-based, digitally supervised prehabilitation program—using 5G and AI—can help gastric cancer patients get fitter before surgery. Participants who have completed chemotherapy and are scheduled for stomach removal will either receive standard care or …

This study tests whether adding telehealth sex therapy to standard pelvic floor physical therapy helps men recover urinary and sexual function after prostate cancer treatment. All participants receive pelvic floor therapy and education on using a vacuum erection device. Half are …

This study tests a nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer who are taking a specific combination of drugs. The program provides education, symptom management tips, and coping strategies over about 12 weeks. Researchers want to see …

This study tests whether an AI-powered program can help older adults with serious illnesses like cancer or heart disease manage emotional distress. Participants receive short videos and daily check-ins from a chatbot that teaches practical coping skills, all from their own phone.…

This trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…

This pilot study tests whether delivering pain medication directly to the spinal cord via an implanted pump can better control severe pain in people with pancreatic cancer. The trial enrolls adults whose pain is not well managed by standard treatments or who cannot take typical p…

This phase III trial tests whether a daily probiotic supplement, OXXYSLAB®, can reduce peripheral neuropathy—nerve damage causing pain and numbness—in people with stage III colon cancer receiving oxaliplatin-based chemotherapy (FOLFOX or XELOX). About 130 participants will take e…

Shortness of breath, or dyspnea, affects most lung cancer patients and often persists despite standard treatments. This pilot study tests a stepped-care behavioral intervention called INSPIRE, which starts with brief coping skills and adds more intensive psychological support onl…

This study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…

This trial tests an experimental drug called VC004 for people with moderate-to-severe pain caused by cancer that has spread to the bones. About 26 adults will receive either a low or high dose of VC004 or a placebo capsule, and researchers will track changes in daily pain scores …

This trial tests whether injecting Botox (abobotulinumtoxin-A) into the forehead muscles just before paramedian forehead flap surgery can improve the cosmetic appearance of the resulting scar. Adults with nasal skin cancer defects needing this reconstruction are randomly assigned…

This study tests whether a mobile-based rehabilitation program, built on the PERMA-H model of well-being, can improve hope, self-confidence, and social support in people recovering from a tracheostomy due to oral cancer. Participants use a WeChat mini-program with a chatbot and t…

This trial investigates whether gentle abdominal massage, performed early after colon cancer surgery, can help the intestines start working again more quickly. Many patients experience a temporary slowdown in gut function (postoperative ileus) that causes bloating, pain, and naus…

This trial tests whether an ultrasound-guided nerve block called QLESP can reduce pain and the need for opioid painkillers after robot-assisted partial nephrectomy for kidney cancer. Adults scheduled for this surgery are randomly assigned to receive either the QLESP block or a st…

This study tests whether taking a high dose of whey protein after each workout helps breast cancer survivors gain more muscle and lose more fat compared to exercise alone. Participants are women aged 20 to 89 who have completed treatment for breast cancer and are prescribed exerc…

This study tests whether an online educational tool called THRIVE, powered by artificial intelligence, can help people newly diagnosed with thyroid cancer feel less anxious and more confident about their treatment choices. Participants use the tool on their own device before meet…

This trial tests whether a short course of precisely targeted radiotherapy can safely reduce severe pain in people with advanced pancreatic cancer. The radiation is aimed at the coeliac plexus, a network of nerves in the abdomen that often causes pain when affected by the tumor. …

This observational study looks at how pancreatic cancer changes immune cells in the blood. Researchers will compare blood samples from 50 people with newly diagnosed, untreated pancreatic cancer to 50 age-matched people with a non-cancerous pancreatic condition. They aim to ident…

This study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…

This study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…

This study looks at whether a structured surveillance program using regular ultrasound and a blood test (alpha-fetoprotein) can detect liver cancer at an earlier, more treatable stage in people at high risk. About 300 adults with liver cirrhosis, chronic hepatitis B, or advanced …

This early-stage study tests whether a magnetic tracer and a fluorescent dye can safely help doctors find lymph nodes where stomach cancer may have spread. About 20 adults with early stomach cancer will receive the injection before surgery. The goal is to see if this method is sa…

This study tests a program called HOLA that teaches oncologists special communication skills to build better relationships with their Latino patients who have advanced cancer. Researchers will compare how strong the bond is between doctors who take the training and those who don'…

This observational study is investigating whether certain blood markers and gut microorganisms can help identify people with chronic pancreatitis who are at higher risk of developing pancreatic cancer. Researchers will compare healthy individuals, those with chronic pancreatitis,…

This study looks at people who had surgery for advanced lower rectal cancer, comparing two procedures: one that removes the rectum and anus (requiring a permanent stoma) and one that removes the rectum but keeps the anus (with a reconnection). The goal is to see which approach le…

This study tests whether a culturally tailored program can help Black women keep their mammogram appointments. About 176 women aged 40 and older who are scheduled for a screening mammogram will take part. The goal is to find better ways to reduce racial disparities in breast canc…

This study will compare how quickly and how much THC enters the blood when people vape THC liquids versus smoking cannabis. Forty healthy adults who already use both products will try each method in a random order. Researchers will measure THC levels, side effects, and puffing be…

This observational study follows Indian adults with resectable non-small cell lung cancer who are prescribed durvalumab as part of their routine care. The goal is to monitor how often patients experience serious side effects, including severe adverse events and other complication…

This study tests whether adding a technique called vascular deformation mapping (VDM) to standard CT scans can better predict liver failure after major liver surgery. Researchers will analyze routine preoperative CT images from over 1,000 adults undergoing removal of at least thr…

This study uses a special PET scan to track a tracer called 89Zr-trastuzumab in people with advanced lung cancer that has HER2 changes. The goal is to see if the tracer builds up differently in tumors with HER2 mutations versus those with too much HER2 protein. About 20 adults wi…

This study follows 75 people with locally advanced non-small cell lung cancer who receive a year of adjuvant immunotherapy after chemoradiotherapy. Researchers will use questionnaires to track changes in quality of life and self-reported health from the start of immunotherapy to …

This study is exploring whether the bacteria in your gut can predict how well a certain type of lung cancer responds to treatment. Researchers are following 100 people with stage II-IIIB non-small cell lung cancer who are receiving chemoimmunotherapy before surgery. The goal is t…

This study looks at whether a combination of immune cell activity, genetic changes, and imaging features can help predict if colorectal cancer that has spread to the liver will come back after surgery. Researchers will analyze tumor tissue, blood samples, and scans from about 210…

This study planned to test whether kidneys with small, low-risk tumors could be removed from donors, have the tumor taken out, and then be transplanted into patients with kidney failure. The goal was to increase the number of available donor kidneys. However, the study was withdr…

This pilot study tests whether the experimental drug casdatifan can alter the activity of genes controlled by HIF-2α in people with advanced clear cell kidney cancer that has stopped responding to prior treatments. Participants take casdatifan daily, and researchers analyze tumor…

This study will collect blood samples from 25 people with small cell lung cancer who are being treated with the drug tarlatamab. Researchers will analyze the samples to learn more about how the drug works, who might benefit most, and how to predict side effects like cytokine rele…

This study asks whether an artificial intelligence system can make the same care recommendations as a team of cancer experts for people with stomach, colon, or rectal cancer. About 69 participants will have their medical information reviewed independently by both the AI and a mul…

This phase 2 trial tests whether a highly sensitive blood test (ctDNA) can help manage treatment for 200 people with early-stage rectal cancer. After standard chemotherapy and radiation, some patients will have their treatment guided by the blood test results instead of immediate…

This study aims to find biological markers in saliva, mouth rinse, blood, or tissue that could help identify and predict the course of oral cancer, gum disease, and tooth decay. Researchers will collect health information and samples from 4,000 adults with these conditions and he…

This registry study follows bladder cancer patients who, after receiving systemic therapy, choose not to undergo bladder removal (cystectomy) or radiotherapy. The goal is to collect data on their outcomes, such as metastasis-free survival, to better understand which patients migh…

This early-phase trial is testing whether injecting a fluorescently labeled version of the immunotherapy drug nivolumab directly into head and neck tumors is safe and helps visualize the tumor and nearby lymph nodes during surgery. Adults with head and neck squamous cell carcinom…

This study looks at whether a new blood test can find tiny bits of tumor DNA left behind after pancreatic cancer surgery. About 30 adults who had their cancer removed will give blood samples at three key times over six months. The goal is to see if this test can detect remaining …

This study is looking at whether a person's traditional Chinese medicine (TCM) constitution—a concept that categorizes individuals into different body types—can help predict who will experience diarrhea as a side effect of combined immunotherapy and targeted therapy for liver can…

This study reviews medical records of 250 people with advanced or metastatic non-small cell lung cancer that has a specific change in the EGFR gene. Researchers want to learn about patients' backgrounds, the treatments they receive, and how well those treatments work. The goal is…

This study is looking at whether analyzing blood, urine, and stool samples can help predict which lung cancer patients are more likely to develop radiation pneumonitis—a type of lung inflammation—after receiving immunotherapy and radiation therapy. The researchers will collect sa…

This study looks at the well-being and medical care of people in Korea who had their bladder removed (radical cystectomy) for bladder cancer. Using nationwide insurance records, researchers will track complications, hospital stays, readmissions, and survival up to three years aft…

This study investigates whether substances in the blood can predict how patients with advanced liver cancer respond to a combination of atezolizumab and bevacizumab. Researchers will analyze leftover blood samples from routine tests in 100 patients to look for patterns linked to …

This trial explores whether a whole-body bone scan (SPECT/CT) taken in the treatment position can help doctors plan stereotactic radiotherapy more precisely for prostate cancer that has spread to the bones. Thirty patients will receive the scan in addition to standard imaging, an…

This study aims to develop a diagnostic model that predicts the risk of colorectal cancer and advanced polyps in adults aged 18 to 80 who are already scheduled for a routine colonoscopy in China. Participants fill out a questionnaire about their lifestyle, medical history, and sy…

This study looks at whether artificial intelligence and detailed molecular analysis can help predict how high-grade serous ovarian cancer will behave after surgery. Researchers will analyze tumor images, genetic data, and patient records from 1,300 women to build a model that for…

This study investigates whether a specialized MRI scan called three-dimensional magnetic resonance elastography (3D-MRE) can predict how well patients with initially unresectable liver cancer will respond to conversion therapy. The scan measures the stiffness and other physical p…

This study looks at 3,000 people who had surgery for colorectal cancer to see how often polyps come back in the colon afterward. Researchers will check if the type and stage of the original cancer are linked to polyp recurrence. The goal is to improve follow-up care by identifyin…

This trial tests whether monitoring sacral reflexes during surgery can predict nerve function afterward. Patients undergoing sacrectomy for pelvic bone cancer or spinal procedures will have their reflexes tracked in real time. The goal is to help surgeons make decisions and prepa…

This study investigates whether different types of exercise can help middle-aged women reduce their body burden of PFAS (environmental chemicals) and improve muscle function. Participants will be assigned to either interval walking or high-intensity circuit training for six month…

This study investigates whether a special 3D MRI scan, called magnetic resonance elastography (3D-MRE), can detect microscopic tumor remnants at the surgical margin after liver cancer removal. Current methods only examine the removed tissue, not the remaining liver. Researchers w…

This trial investigates whether a special type of MRI scan, called DCE-MRI, can better assess how well chemotherapy is working in people with borderline resectable pancreatic cancer. Participants will receive standard chemotherapy and undergo DCE-MRI scans along with regular imag…

This study explores whether a special 3D MRI scan, called magnetic resonance elastography, can measure liver stiffness and elasticity before surgery to predict the risk of liver failure afterward. Researchers will enroll 150 adults with liver cancer or liver metastases who are sc…

This study observes people with a common type of advanced breast cancer (HR+/HER2-) who are already on standard hormone therapy. Researchers use simple blood tests to look for changes in the ESR1 gene, which can make the cancer stop responding to treatment. By tracking these muta…

This study investigates whether two blood-based biomarkers—circulating tumor DNA (ctDNA) and tumor-educated platelets (TEP)—can predict how well colon cancer responds to pre-surgery therapy. About 80 adults with stage III colon cancer will provide extra blood samples before, duri…

This study follows 400 people with esophageal squamous cell carcinoma who have received chemo-immunotherapy before surgery. During standard tumor removal, surgeons will carefully label and analyze each lymph node station to see which ones still contain cancer. The goal is to map …

This study takes leftover tumor samples from people with EGFR-mutant non-small cell lung cancer and grows them in the lab as cell cultures and organoids. Researchers will test different anti-EGFR drugs on these models to see which ones work best for each type of mutation and expl…

This pilot study looks at how different resistance training routines change levels of myokines—molecules released by muscles during exercise—in women who have finished breast cancer treatment. Participants will be assigned to one of three exercise regimens (conditioning, strength…

This study looks at how certain cancers develop in people with HIV and what factors might increase their risk. Researchers will analyze medical data from 1,000 HIV-positive adults to track which types of cancer occur most often and why. The goal is to improve early detection and …

This study investigates why some stomach cancers do not respond to a standard chemotherapy combination (FLOT) plus the immunotherapy drug durvalumab. Researchers will analyze tumor samples and blood from 250 patients with operable stomach or gastroesophageal junction cancer. By m…

This study is developing a way to predict who might develop a serious jaw bone condition called medication-related osteonecrosis of the jaw (MRONJ) after dental procedures. Researchers are following adults who have taken bone-strengthening drugs like bisphosphonates or denosumab …

This study investigates whether substances in saliva, specifically interleukin-6 levels and certain gene variations, can indicate whether oral cancer has spread to lymph nodes in the neck. Researchers will collect saliva samples from adults with oral squamous cell carcinoma befor…

This study investigates whether adding environmental exposure risk assessments to standard care is useful and acceptable for women at average or high risk of breast cancer, as well as those diagnosed with early-onset breast cancer. Researchers will survey patients and providers a…

This study is developing an AI tool that analyzes tumor images, proteins, and patient data to predict whether a person with advanced HER2-positive or low-expression breast cancer will benefit from the targeted drug T-DXd. The goal is to avoid giving ineffective treatment, which c…

This study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…

This study looks at how well a chemotherapy and immunotherapy combination works for early triple-negative breast cancer when the usual anthracycline drugs are left out. The researchers are focusing on patients who cannot take anthracyclines due to previous treatment, older age, o…